Drug Profile
CJ 14199
Alternative Names: CJ-14199Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator CJ Cheiljedang Corp.
- Developer HK inno.N
- Class Hepatoprotectants; Irritable bowel syndrome therapies
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Constipation; Irritable bowel syndrome; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in South Korea (PO)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 28 Oct 2019 No recent reports of development identified for preclinical development in Constipation in South Korea (PO)